Breast cancer hypo-fractionated radiotherapy offers long-term tumour control

Extending adjuvant trastuzumab treatment time provided no additional benefit

BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

Potential targets and complications of apoptosis and necrosis

Prognostic signatures in colon cancer

Targeting the proteasome mechanism

Effect of hypoxia on cancer progression and adaptive response

New agents and mTOR inhibitors

Oncogenes and genetic aberration

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Transcriptional regulation of endothelial cell differentiation